Obseva Sa (OBSV)

Trade OBSV now with
3/15/2023 2:10:11 AM ObsEva Announces Plans To Consolidate Operations In Switzerland: Delisting Of OBSV From Nasdaq Effective Mar 23
3/13/2023 2:08:14 AM ObsEva: Ernest Loumaye Appointed As Interim Chairman
12/19/2022 7:18:45 AM Competent Court In Geneva Grants ObsEva's Request To Withdraw Moratorium Considering That Company Is No Longer Over-indebted
11/22/2022 1:03:42 AM ObsEva Announces Sale Of Ebopiprant License Agreement To XOMA For Up To $113 Mln
10/13/2022 1:18:30 AM ObsEva Announces IND Approval For Yuyuan Bioscience's Phase 1 Clinical Trial Of Nolasiban In China
9/13/2022 1:04:06 AM ObsEva Announces Progress On Restructuring Initiatives; Sees $7.6 Mln Annual Savings
8/22/2022 1:04:51 AM ObsEva Receives Nasdaq Non-Compliance Notice
6/17/2022 1:04:36 AM ObsEva: EC Grants Marketing Authorization For Yselty For Treatment Of Uterine Fibroids
5/17/2022 1:06:11 AM ObsEva Q1 Net Loss $11.8 Mln Or $0.14/Shr Vs Loss $20.0 Mln Or $0.29/Shr Last Year
5/9/2022 1:06:18 AM ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix For Uterine Fibroids At The 2022 ACOG ACSM
5/2/2022 1:04:23 AM ObsEva Appoints Brandi Howard As Chief Clinical Officer, Effective May 9